Current therapies for malignant pleural mesothelioma
Open Access
- 28 February 2008
- journal article
- special feature
- Published by Springer Nature in Environmental Health and Preventive Medicine
- Vol. 13 (2) , 75-83
Abstract
Mesothelioma is a highly lethal tumor derived from mesothelial cells, and its global incidence is increasing because of widespread exposure of numerous individuals to asbestos in the last 50 years. Mesothelioma is largely untreatable with any of the therapeutic modalities. Recently, a novel multitargeted antifolate pemetrexed has shown promising activity against malignant pleural mesothelioma, producing response rates of up to 40% when used in combination with cisplatin. In a large phase III study, use of a combination of pemetrexed and cisplatin was associated with significantly improved survival time and with greater antitumor activity compared with cisplatin alone. This combination also gave a significant response rate of approximately 50% in patients with epithelioid malignant pleural mesothelioma. These clinical benefits of pemetrexed–cisplatin doublet have changed the perception of mesothelioma chemotherapy. Other combinations, including gemcitabine in combination with cisplatin, have also shown encouraging response rates. Prognosis depends on gender, clinical stage of the tumor, histological subtype, platelet count, leukocyte counts, and performance status. Radiotherapy can palliate mesothelioma patients with chest pain, and has been indicated to be of benefit for the prevention of malignant seeding along the tract of a chest tube or needle biopsy. Trimodality treatment using extrapleural pneumonectomy, radiation and chemotherapy has shown promising therapeutic value. The development of chemotherapeutic regimens and the favorable outcomes of trimodality have led to new combined modality trials. In Japan, multicenter national trials against mesothelioma will begin in the near future.Keywords
This publication has 44 references indexed in Scilit:
- Dosimetric verification for intensity-modulated radiotherapy of thoracic cancers using experimental and Monte Carlo approachesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]FluorodeoxyglucoseJournal of Clinical Oncology, 2006
- Irinotecan for malignant mesotheliomaLung Cancer, 2005
- Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2004
- Radical surgery for mesotheliomaBMJ, 2004
- P-517 A phase II study of irinotecan, cisplatin, and mitomycin C (IPM) in malignant pleural mesotheliomaLung Cancer, 2003
- Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesotheliomaEuropean Journal of Cancer, 2000
- Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesotheliomaCancer, 1999
- Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesotheliomaCancer, 1997
- Radiation sensitivity of human lung cancer cell linesEuropean Journal of Cancer and Clinical Oncology, 1989